Teclistamab

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
木曜日, 5月 9, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Investment, Teclistamab, Partnership, Myasthenia gravis, Trial of the century, Growth, Hook effect, ASCO, Journal, Lung cancer, Graves' ophthalmopathy, Pharmacokinetics, National Medical Products Administration, Conference, Fluorouracil, Patent, Telephone, NSCLC, Merck Group, Safety, Pembrolizumab, Artificial intelligence, CEACAM5, Autoimmune disease, Immunology, Monoclonal antibody, Clinical trial, University, TED, Sale, Chicken, Bystander effect, Antigen, Neonatal Fc receptor, Patient, Society, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
  • “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base.
  • General and administrative expense was $8.3 million for the first quarter of 2024, compared with $8.2 million for the same period in 2023.
  • As of March 31, 2024, OmniAb had cash, cash equivalents and short-term investments of $69.0 million.

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
水曜日, 3月 20, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Research, Multiple myeloma, Lung cancer, Partner, NMPA, Growth, NSCLC, CIDP, Partnership, Telephone, GSK, Patient, TED, NASDAQ Biotechnology Index, Epitope, Artificial intelligence, Sale, Myasthenia gravis, Neonatal Fc receptor, Fluorouracil, Graves' ophthalmopathy, Investment, Teclistamab, NBI, National Medical Products Administration, Johnson & Johnson, Drug development, Safety, Chicken, Machine learning, Gastrointestinal cancer, Immunoglobulin G, BLA, Chronic inflammatory demyelinating polyneuropathy, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
  • OmniAb launched two new technologies during 2023 including OmniDeep™ and, during the fourth quarter, OmnidAb™.
  • Fourth quarter 2023 and recent partner highlights include the following:
    Immunovant reported positive initial results for batoclimab in Graves’ disease (GD).
  • OmniAb was added to the Nasdaq Biotechnology Index (NBI) in the fourth quarter.

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
木曜日, 11月 9, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Neonatal Fc receptor, A1, Food, Protein engineering, Interest, European, Serum albumin, Teclistamab, Sale, Arcus, Cancer, Gilead Sciences, Marketing, GSK, Investment, Patient, Exploratory research, Financial result, Novartis, Immunoglobulin G, FDA, PD-L1, Trial of the century, Cervical cancer, NMPA, Fast Track, American Society of Clinical Oncology, Regulation of tobacco by the U.S. Food and Drug Administration, Society, Foundation for Research & Technology – Hellas, Pharmaceutical industry, Arms industry, Reinsurance, Vaccine, Polaris

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2023, and provided operating and partner program updates.
  • As of September 30, 2023, OmniAb had cash, cash equivalents and short-term investments of $96.6 million.
  • Financial results prior to November 1, 2022, are presented on a carve-out basis derived from Ligand’s historical accounting records, as if OmniAb were an independent company.
  • OmniAb management will review third quarter 2023 financial results as part of a Research & Technology virtual event being held today at 11:00 a.m. Eastern time.

Florida Cancer Specialists & Research Institute Launches Advanced Cellular Therapy Program to Treat Recurring Blood Cancers

Retrieved on: 
火曜日, 10月 31, 2023
Patient, Bispecific monoclonal antibody, CD3, Multiple myeloma, Food, Therapy, Hope, Bone marrow, BCPS, News, Infection, Teclistamab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, RRMM, Quality of life, Disease, Immune system, Doctor of Pharmacy, Cancer, FCS, Nursing, Pharmaceutical industry, Vaccine, Hospital, MD

FORT MYERS, Fla., Oct. 31, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma (RRMM). The treatment, teclistamab (TECVAYLI®), is a type of rapidly evolving cancer therapy that uses the body's immune system to fight cancer. FCS is the first oncology care provider in Sarasota County to offer the maintenance program, with plans to expand to other FCS sites across Florida in the coming months.

Key Points: 
  • FORT MYERS, Fla., Oct. 31, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) is now offering an advanced maintenance therapy program that slows the progression of relapsed/refractory multiple myeloma (RRMM).
  • The treatment, teclistamab (TECVAYLI®), is a type of rapidly evolving cancer therapy that uses the body's immune system to fight cancer.
  • In clinical research trials, 62 percent of patients had a favorable response to this therapy."
  • These therapies work by binding to special proteins that allow the immune system to recognize and kill cancer cells.

OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
木曜日, 8月 10, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Biologics license application, GSK, Drug development, Neurocrine Biosciences, Stanford University, GMG, Telephone, Clinical trial, Merck & Co., DSM-IV codes, Sale, Graves' ophthalmopathy, AML, Investigational New Drug, Chronic inflammatory demyelinating polyneuropathy, Azacitidine, Investment, Patient, Financial result, European, National Medical Products Administration, Merck, Teclistamab, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neonatal Fc receptor, NMPA, Safety, Therapy, Food, Conference, Cryptocurrency, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2023, and provided operating and partner program updates.
  • “Our business continued to grow and perform well during the second quarter with advancements in business development and progress across partner programs.
  • Revenue for the second quarter of 2023 was $6.9 million, compared with $7.2 million for the same period in 2022.
  • During the second quarter of 2023, OmniAb entered into four new license agreements including with Merck & Co., Inc., Neurocrine Biosciences Inc., Stanford University and Seattle Children’s Hospital.

SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
水曜日, 8月 2, 2023
KRAS, Plantar fibromatosis, Marketing, Neoplasm, New Drug Application, Janssen, G&A, MEK, Cycle, Pain, Congress, Nirogacestat, RAS, Patient, Janssen Pharmaceuticals, Research and development, R, Prescription Drug User Fee Act, European Hematology Association, Multiple myeloma, MAPK, Decentralized finance, Research, GSK plc, PDUFA, Growth, Teclistamab, FDA, Common, RAF, NRAS, Solar cycle 10, GSK, AACR, CD3, Cancer, American Association for Cancer Research, BRAF, Solar cycle 2, TEAD, Administration, RRMM, Therapy, NDA, ASCO, American Society of Clinical Oncology, Annual general meeting, EHA, Mouse, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, BCMA, Pharmaceutical industry

STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported second quarter financial results for the period ended June 30, 2023 and provided an update on recent company developments.

Key Points: 
  • STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported second quarter financial results for the period ended June 30, 2023 and provided an update on recent company developments.
  • In May 2023, SpringWorks announced full enrollment of the Phase 2 trial evaluating nirogacestat as a monotherapy in patients with recurrent ovarian granulosa cell tumors.
  • SpringWorks expects to file an Investigational New Drug Application for SW-682 in the fourth quarter of 2023.
  • Net Loss Attributable to Common Stockholders: SpringWorks reported net loss of $77.9 million, or $1.25 per share, for the second quarter of 2023.

Vizient: Expansion of Specialty Drugs Driving a 3.42% Projected Increase in Hospital Pharmacy Spend

Retrieved on: 
火曜日, 8月 1, 2023
Medical Supplies, Medical Devices, Health, Hospitals, Practice Management, Pharmaceutical, Rituximab, Bevacizumab, Migraine, Drug development, Trastuzumab, Ustekinumab, Adalimumab, Cancer, Remdesivir, CGRP, Multimedia, Pharmacy, Multiple sclerosis, Outlook, Acquisition, COVID-19, Patient, Tebentafusp, Teclistamab, FDA, News, Calcitonin, Pharmaceutical industry, Generic drug, Denosumab, Vizient, Inc., Ocrelizumab

Vizient, Inc. projects a 3.42% increase in hospital pharmaceutical spend in its Summer Pharmacy Market Outlook, released July 31.

Key Points: 
  • Vizient, Inc. projects a 3.42% increase in hospital pharmaceutical spend in its Summer Pharmacy Market Outlook, released July 31.
  • The overall increase, forecasted for the year beginning January 2024, is being driven by specialty pharmaceuticals and medications in the neurology service line.
  • “Specialty medications overall accounted for 51% of spending in 2022,” said Carina Dolan, associate vice president, clinical oncology, pharmacoeconomics & market insights.
  • Projections in the Vizient Pharmacy Market Outlook are based on the top 85% of Vizient Pharmacy Program participants’ aggregated purchasing volume.

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

Retrieved on: 
土曜日, 6月 3, 2023
Neutropenia, Bispecific monoclonal antibody, Antigen, Pi, Therapy, Progression-free survival, CRS, Immunomodulatory imide drug, Aes, Tel Aviv Sourasky Medical Center, EMD, PFS, ASCO, Incidence, American Society of Clinical Oncology, Multiple myeloma, Cytokine release syndrome, Patient, NE, Anemia, Janssen Pharmaceuticals, Annual general meeting, Confidence interval, Johnson & Johnson, RRMM, Teclistamab, Abstract, Thrombocytopenia, Society, ORR, Pharmaceutical industry

"By combining teclistamab and talquetamab, two bispecific antibodies that have demonstrated high efficacy responses in targeting distinct antigens, we evaluated the potential of this unique combination regimen for patients who were resistant or refractory to multiple lines of therapy," said Yael Cohen, M.D., Head of Myeloma Unit, Hematology Institute, Tel-Aviv Sourasky Medical Center, Israel, and principal study investigator.† "The high overall response rates characterized in this study are encouraging and support the continued evaluation of this regimen as a combination therapy."

Key Points: 
  • "By combining teclistamab and talquetamab, two bispecific antibodies that have demonstrated high efficacy responses in targeting distinct antigens, we evaluated the potential of this unique combination regimen for patients who were resistant or refractory to multiple lines of therapy," said Yael Cohen, M.D., Head of Myeloma Unit, Hematology Institute, Tel-Aviv Sourasky Medical Center, Israel, and principal study investigator.† "The high overall response rates characterized in this study are encouraging and support the continued evaluation of this regimen as a combination therapy."
  • The incidence and severity of CRS were consistent with TECVAYLI® and talquetamab monotherapy treatment.1
    "Multiple myeloma becomes progressively more difficult to treat as patients relapse or become refractory to treatment.
  • The RedirecTT-1 data suggest the use of bispecific antibodies with high activity in myeloma, TECVAYLI and talquetamab, may have potential to yield high efficacy responses in this patient population," said Arnob Banerjee, M.D., Ph.D., Global Medical Head, Early Development Oncology, Janssen Research & Development, LLC.
  • "The promising preliminary results observed with the combination, even in patients with extramedullary disease, are highly supportive of continued investigation and reinforce our commitment to evaluate and develop combination regimens built on our deep disease understanding and portfolio of therapeutics."

SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress

Retrieved on: 
木曜日, 5月 11, 2023
Neutropenia, GSK, Arm, SCR, European Hematology Association, Diarrhea, CD3, CRS, Immunomodulatory imide drug, Multiple myeloma, Cancer, Janssen, Nomenclature of monoclonal antibodies, KVA, ASCO, Congress, Nirogacestat, GSK plc, American Society of Clinical Oncology, Cytokine release syndrome, Patient, Anemia, Janssen Pharmaceuticals, Annual general meeting, EHA, CR, Toxic leukoencephalopathy, RRMM, Teclistamab, FDA, Therapy, Society, ORR, BCMA, Safety, Fatigue, Pharmaceutical industry

“These data provide further validation of the mechanistic approach supporting nirogacestat’s ability to enhance the activity of BCMA-directed therapies across modalities.

Key Points: 
  • “These data provide further validation of the mechanistic approach supporting nirogacestat’s ability to enhance the activity of BCMA-directed therapies across modalities.
  • We are pleased that updated data from the GSK-sponsored trial continue to support our thesis that the combination with nirogacestat may further optimize the benefit-risk profile of belamaf monotherapy.
  • “This is the first clinical data set of nirogacestat in combination with a BCMA bispecific agent.
  • “Nirogacestat is being evaluated in combination with three other bispecific agents and we look forward to generating more data with these combinations.”

OmniAb Reports First Quarter 2023 Financial Results and Business Highlights

Retrieved on: 
木曜日, 5月 11, 2023
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Scripps Research, Drug development, Neoplasm, Telephone, Health care, European Medicines Agency, Neurocrine Biosciences, Medication, Protein engineering, Marketing, Sale, Biology, Seagen, Graves' ophthalmopathy, Investigational New Drug, Chronic inflammatory demyelinating polyneuropathy, Investment, Machine learning, Financial result, LDL, Immunoglobulin G, European, National Medical Products Administration, United Kingdom, AI, Teclistamab, Society, Conference, Pharmaceutical industry, Vaccine, Expo, Greater China

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2023, and provided operating and partner program updates.
  • On November 1, 2022, OmniAb completed a spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), resulting in OmniAb becoming an independent publicly traded company.
  • Financial results prior to November 1, 2022, are presented on a carve-out basis derived from Ligand’s historical accounting records, as if OmniAb were an independent company.
  • First quarter 2023 and recent partner highlights include the following:
    Immunovant announced that it expects to report initial results from its Phase 2 clinical trial in Graves’ disease in the second half of 2023.